MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway
- Type
- Retraction
- Notice date
- 8/24/2022 0:00
- Journal
- Frontiers in Physiology
- Publisher
- Frontiers
- Notice DOI
- 10.3389/fphys.2022.1020568
- Original paper DOI
- 10.3389/fphys.2021.646903